VNRX קפיטליזציה חשבונאית VolitionRx

VolitionRx Limited (VNRX) generates revenue by integrating liquid biopsy systems into clinical protocols, ensuring steady demand for ancillary materials. Meanwhile, the company is competing for methodological precision against major medical behemoths and laboratories. Production facility capacities are fully utilized, and equipment has been upgraded. The current metric stands at -0.07, which demonstrates the price visualization.

Book value capitalization measures the net value of assets minus all liabilities, reflecting the issuer's actual internal resource potential. For VolitionRx Limited (VNRX), this metric demonstrates financial stability during the market launch of the Nu.Q diagnostic test, allowing investors to assess the efficiency of capital management through the movement of the company's book capital prior to the commercial sales scaling phase.